NewGenIvf closes $1.25M public offering at $0.07 per share

NewGenIvf Group Limited (NASDAQ: NIVF) closed a public offering on September 30, 2026, raising approximately $1.25 million in gross proceeds before placement agent fees and other expenses.

The offering consisted of 17,857,143 Class A Ordinary Shares or pre-funded warrants, comprising 125,000 Class A Ordinary Shares and pre-funded warrants to purchase up to 17,732,143 Class A Ordinary Shares. The public offering price was $0.07 per Class A Ordinary Share and $0.06999 per pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until exercised in full.

The company said it plans to use the net proceeds for investment in K25.ai, restructuring of debt securities, working capital including manufacturing and deployment of Nodexus machines in its cell-sorting business, and general corporate purposes.

A registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission on August 20, 2026 was declared effective on September 28, 2026. Aegis Capital Corp. acted as exclusive placement agent for the offering. Han Kun Law Offices LLP served as U.S. counsel to the company, and Kaufman & Canoles, P.C. served as U.S. counsel to Aegis Capital Corp.

Bangkok-based NewGenIvf operates across real estate development, digital asset management, and reproductive health services.

You May Also Be Interested In

• Google: Introducing Gemini 4 Argon
• FORT Robotics files draft S-4 for SPAC merger at $557M value
• Magic Empire closes $3M registered direct offering on Nasdaq